Safety Limits Enthusiasm

The FDA approval is positive, but label language or early real-world tolerability data leads physicians to proceed cautiously. Commercial expectations are revised down if adverse-event monitoring becomes a central launch issue.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.